IBEX 35
11.154,60 +170,90 (+1,56%) Euro Stoxx 50
5.006,85 +67,84 (+1,37%) Dólar/Euro
1,0699 -0,0034 (-0,32%) Petróleo Brent
89,36 +0,35 (+0,39%) Oro
2.349,60 +7,10 (+0,30%) Bitcoin EUR
58.770,89 -1.632,55 (-2,70%)
Geron Corporation (GERN)
Después del cierre:
Geron Corporation
919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 141
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1,36M | N/A | 1951 |
| Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | 340,98k | N/A | 1967 |
| Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 827,01k | N/A | 1964 |
| Mr. Scott Samuels | Executive VP, Chief Legal Officer & Corporate Secretary | 485,32k | N/A | N/A |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | N/A | N/A |
| Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | N/A | 1975 |
| Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753,22k | N/A | 1964 |
| Mr. Anil Kapur | Executive VP of Corporate Strategy & Chief Commercial Officer | 654,89k | N/A | 1970 |
| Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | N/A | 1962 |
| Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | N/A | 1983 |
Descripción
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Gobierno corporativo
El ISS Governance QualityScore de Geron Corporation, a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 9; Compensación: 6.
